Q1 FY2027 Financial Summary (Consolidated) [Japanese GAAP]

Overview of results

Consolidated net sales for the quarter were 587,612 thousand yen, down year over year. Operating loss was 130,261 thousand yen, ordinary loss 106,092 thousand yen, and net loss attributable to owners of the parent 107,018 thousand yen. By segment, the regenerative medicine-related business posted substantial increases in both revenue and profit, while the cosmetics business, Beauty & Wellness, and sustainability businesses saw revenue declines and expanded losses. Ongoing reevaluation of the medium‑term plan and strengthening of the financial base are being pursued.

Outlook and financial measures

We are rebuilding the medium-term management plan to optimize the portfolio based on investment efficiency and market growth. We will push for fundamental restructuring of low‑profit businesses, high value-added strategies in cosmetics and beauty, new product development in regenerative medicine, and selectivity and concentration in the sustainability business. In terms of capital policy, we will consider flexible responses including use of external funds to strengthen the financial base and risk management.